跳转至内容
Merck
CN
所有图片(1)

主要文件

查看所有文档

安全信息

1477003

USP

制霉菌素即用型溶液

United States Pharmacopeia (USP) Reference Standard

别名:

制霉素, 制霉菌素

登录查看公司和协议定价
所有图片(1)

About This Item

CAS号:
1400-61-9
MDL编号:
MFCD25541651
UNSPSC代码:
41116107
PubChem化学物质编号:
329750594
NACRES:
NA.24

等级

pharmaceutical primary standard

API类

nystatin

制造商/商品名称

USP

应用

pharmaceutical (small molecule)

包装形式

neat

SMILES字符串

O[C@@H]([C@H](C)[C@H](C)O1)[C@@H](C)/C=C/C=C/CC/C=C/C=C/C=C/C=C/[C@H](O[C@@H]2O[C@H](C)[C@@H](O)[C@H](N)[C@@H]2O)C[C@@]3([H])[C@H](C(O)=O)[C@@H](O)C[C@](O)(O3)C[C@@H](O)[C@H](O)CC[C@@H](O)C[C@@H](O)C[C@@H](O)CC1=O

InChI

1S/C47H75NO17/c1-27-17-15-13-11-9-7-5-6-8-10-12-14-16-18-34(64-46-44(58)41(48)43(57)30(4)63-46)24-38-40(45(59)60)37(54)26-47(61,65-38)25-36(53)35(52)20-19-31(49)21-32(50)22-33(51)23-39(55)62-29(3)28(2)42(27)56/h5-6,8,10-18,27-38,40-44,46,49-54,56-58,61H,7,9,19-26,48H2,1-4H3,(H,59,60)/b6-5+,10-8+,13-11+,14-12+,17-15+,18-16+/t27-,28+,29-,30+,31+,32+,33+,34-,35+,36+,37-,38-,40+,41-,42+,43+,44-,46-,47+/m0/s1

InChI key

VQOXZBDYSJBXMA-QEKUPDCNSA-N

正在寻找类似产品? 访问 产品对比指南

应用

Nystatin USP reference standard suitable for use in specified USP compendial quality tests and assays.

Also used to prepare standard, and system suitability solution for the assay, composition analysis and content uniformity by using liquid chromatography in conjunction with UV detector according to the given below monographs of United States Pharmacopeia (USP): 
  • Nystatin, Neomycin Sulfate, Thiostrepton, and Triamcinolone Acetonide Ointment
  • Nystatin Oral Suspension
  • Nystatin

生化/生理作用

作用机制：制霉菌素通过与真菌细胞膜中的麦角甾醇结合，增加膜的渗透性和产生基于制霉菌素/麦角甾醇的离子通道起作用。 它还可作为脂筏抑制剂和膜相关胆固醇。

抗菌谱：制霉菌素可对抗真菌、酵母和霉菌。

注意

Nystatin in tissue culuture media is stable at 37°C for three days. It is also stable in moderately alkaline media. Solutions and aqueous suspensions begin to lose activity soon after preparation, with heat, light, and oxygen accelerating the decomposition. Aqueous suspensions are stable for 10 minutes when heating to 100°C at pH 7.
Nystatin is soluble at 28°C in methanol (11.2 mg/mL), ethanol (1.2 mg/mL), carbon tetrachloride (1.23 mg/mL), chloroform (0.48 mg/mL), benzene (0.28 mg/mL), and ethylene glycol (8.75 mg/mL). It is also soluble in DMSO at 5 mg/mL and freely soluble in DMF and formamide. It is not recommended to autoclave or sterile filter solutions of Nystatin. Nystatin is also effective as a suspension, stable at 37°C for 3 days. Prepare 50 mg/mL stock suspensions in water and store at -20°C. ?

分析说明

These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.  ​

其他说明

This product is part of the USP Biologics program.

法律信息

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

相关产品

产品编号
说明
价格

储存分类代码

11 - Combustible Solids

WGK

WGK 2

闪点(°F)

Not applicable

闪点(°C)

Not applicable

法规信息

监管及禁止进口产品

从最新的版本中选择一种：

分析证书(COA)

Lot/Batch Number

抱歉，我们目前尚未线上提供该产品的COA。

如需帮助，请联系 客户支持

已有该产品？

在文件库中查找您最近购买产品的文档。

访问文档库

Nystatin
USP43-NF38: United States Pharmacopeia and National Formulary
United States Pharmacopeia, 47(1) (2022)
Nystatin Oral Suspension
USP43-NF38: United States Pharmacopeia and National Formulary
United States Pharmacopeia, 34(1), 3221-3221 (2013)
Nystatin, Neomycin Sulfate, Thiostrepton, and Triamcinolone Acetonide Ointment
USP43-NF38: United States Pharmacopeia and National Formulary
United States Pharmacopeia, 49(4), 3223-3223 (2013)
David Isaacs
Current opinion in infectious diseases, 21(3), 246-250 (2008-05-02)
To examine recent evidence on the efficacy of antifungal prophylaxis to prevent neonatal systemic fungal infection. The review also aims to examine other relevant data, including the incidence of fungal infection, adverse effects of antifungal therapy and avoidable risk factors.
P C Gøtzsche et al.
The Cochrane database of systematic reviews, (2)(2), CD002033-CD002033 (2002-06-22)
Nystatin is sometimes used prophylactically in patients with severe immunodeficiency or in the treatment of fungal infection in such patients, although the effect seems to be equivocal. To study whether nystatin decreases morbidity and mortality when given prophylactically or therapeutically
查看所有相关文献

我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门